This study used pupillometry to provide an objective assessment of a form of synesthesia in which people see additional color when reading numbers. It provides convincing evidence that subjective ...

Fallout 76 The Backwoods Update now live as version 2.20, and this adds a slew of content and applies sweeping balance ...

A new storyline is about to begin with episode 22 of the Sword of the Demon Hunter: Kijin Gentosho anime. To mark the occasion and prepare everyone for the Meiji arc, a new visual was revealed along ...

🕹️ Try and Play with VAR! We provide a demo website for you to play with VAR models and generate images interactively. Enjoy the fun of visual autoregressive modeling! We provide a demo website for ...

An Ocular Therapeutix drug developed for the wet form of age-related macular degeneration was better at helping patients maintain vision compared to a blockbuster Regeneron Pharmaceuticals drug that ...

Ocular Therapeutix (OCUL) lost ~22% in the premarket on Tuesday after the company released data from a late-stage trial evaluating Axpaxli, its experimental therapy for wet age-related macular ...

Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched position in wet age-related macular degeneration (AMD) with investigational ...

Axpaxli shows modest advantage over Eylea in trial Retinal specialists may value trial data more than investors, analyst says Ocular plans FDA discussions and marketing application The ...

First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to an approved anti-VEGF treatment Superiority primary endpoint met with 74.1% ...

Ocular Therapeutix on Tuesday said its experimental Axpaxli eye disease drug succeeded in a Phase 3 study, outperforming a low dose of the blockbuster medicine Eylea. The trial followed 344 patients ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...